Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey.

Angiogenesis plays a key role in various physiological and pathological processes, including inflammation and tumor growth. Numerous angiogenic growth factors (AGFs) have been identified. Usually, the angiogenic process is assumed to represent the outcome of a straightforward interaction of AGFs with specific signalling receptors of the endothelial cell (EC) surface. Actually, the mechanisms by which AGFs induce neovascularization are much more complex. Indeed, angiogenesis is the result of the simultaneous actions of various AGFs and angiogenesis modulators; multiple EC surface receptors with different structure and biological properties are engaged by AGFs to exert a full angiogenic response; AGFs bind a variety of free and immobilized proteins, polysaccharides, and complex lipids of the extracellular milieu that affect AGF integrity, stability, and bioavailability; some of the AGF-binding molecules interact also with AGF receptors. In this review the authors summarize literature data and discuss the current knowledge about the extracellular molecules able to interact with AGFs, thus representing possible key regulators of the angiogenesis process and targets/templates for the development of novel antiangiogenic drugs. This work represents an attempt to highlight common theme in the AGF interactome that occurs at the extracellular level during neovascularization.

[1]  Erwin G. Van Meir,et al.  The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. , 2005, Neuro-oncology.

[2]  L. Aguilar,et al.  Induction of a CXCL8 binding site on endothelial syndecan-3 in rheumatoid synovium. , 2005, Arthritis and rheumatism.

[3]  D. Edwards,et al.  Metalloproteinases and their inhibitors in tumor angiogenesis , 2005, International journal of cancer.

[4]  G. Pilkington,et al.  Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. , 1996, Cancer letters.

[5]  Marco Presta,et al.  Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. , 2003, Blood.

[6]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[7]  Gunilla Westergren-Thorsson,et al.  Tumour necrosis factor‐α interacts with biglycan and decorin , 2002 .

[8]  J. Bonner,et al.  Inhibition of Platelet-derived Growth Factor-BB-induced Fibroblast Proliferation by Plasmin-activated -Macroglobulin Is Mediated via an -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein-dependent Mechanism (*) , 1995, The Journal of Biological Chemistry.

[9]  Luigi Buonaguro,et al.  HIV‐1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix‐associated heparan sulfate proteoglycans through its basic region , 1997, AIDS.

[10]  C. Kumar Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. , 2003, Current drug targets.

[11]  Byungkyu Brian Park,et al.  Visualization and analysis of protein interactions , 2003, Bioinform..

[12]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[13]  A. Joseph,et al.  Scatter factor binds to thrombospondin and other extracellular matrix components. , 1996, The American journal of pathology.

[14]  S. Schultz-Cherry,et al.  Transforming growth factor-beta complexes with thrombospondin. , 1992, Molecular biology of the cell.

[15]  M. Stevens,et al.  INVOLVEMENT OF α-2-MACROGLOBULIN RECEPTOR IN CLEARANCE OF INTERLEUKIN 8–α-2-MACROGLOBULIN COMPLEXES BY HUMAN ALVEOLAR MACROPHAGES , 2000 .

[16]  R. Kalluri,et al.  Endogenous inhibitors of angiogenesis. , 2005, Cancer research.

[17]  Marco Presta,et al.  Antiangiogenic Activity of Semisynthetic Biotechnological Heparins: Low-Molecular-Weight–Sulfated Escherichia coli K5 Polysaccharide Derivatives as Fibroblast Growth Factor Antagonists , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[18]  M. Simons,et al.  Syndecan-4-mediated signalling. , 2001, Cellular signalling.

[19]  F. Soncin Angiogenin supports endothelial and fibroblast cell adhesion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Giacca,et al.  Multiple Interactions of HIV-I Tat Protein with Size-defined Heparin Oligosaccharides* , 1999, The Journal of Biological Chemistry.

[21]  G. Neufeld,et al.  The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. , 2002, Trends in cardiovascular medicine.

[22]  S. Kitano,et al.  Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor , 2002, Cancer Gene Therapy.

[23]  J. Waltenberger,et al.  Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. , 1998, Experimental cell research.

[24]  N. Ortéga,et al.  Extracellular matrix‐bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Salman Rahman,et al.  Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells. , 2005, BMC cell biology.

[26]  M. Nugent,et al.  Nuclear localization of basic fibroblast growth factor is mediated by heparan sulfate proteoglycans through protein kinase C signaling , 2003, Journal of cellular biochemistry.

[27]  T. Arima,et al.  Identification of nucleolin as a binding protein for midkine (MK) and heparin-binding growth associated molecule (HB-GAM). , 1994, Journal of biochemistry.

[28]  D. Sheppard,et al.  The Lymphangiogenic Vascular Endothelial Growth Factors VEGF-C and -D Are Ligands for the Integrin α9β1* , 2005, Journal of Biological Chemistry.

[29]  J. Tiesman,et al.  Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. , 1993, The Journal of biological chemistry.

[30]  S. Soker,et al.  Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. , 1994, Biochemical and biophysical research communications.

[31]  I. Zachary,et al.  Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis. , 2001, Biochemical and biophysical research communications.

[32]  M. Iruela-Arispe,et al.  ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165* , 2003, Journal of Biological Chemistry.

[33]  G. Neufeld,et al.  Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165 * , 1999, The Journal of Biological Chemistry.

[34]  M. Hahne,et al.  Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation , 2005, Cell Death and Differentiation.

[35]  T. Deuel,et al.  Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. , 1999, Current opinion in hematology.

[36]  Marco Presta,et al.  Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV‐1 Tat protein antagonists , 2004, FEBS letters.

[37]  D. Coppola,et al.  Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors , 2004, Oncogene.

[38]  R. Yu,et al.  Role of tumor-associated gangliosides in cancer progression. , 2003, Biochimie.

[39]  C. Rüegg,et al.  Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.

[40]  P. Comoglio,et al.  Cancer therapy: can the challenge be MET? , 2005, Trends in molecular medicine.

[41]  Guoping Wu,et al.  Platelet Factor 4 and Interleukin-8 CXC Chemokine Heterodimer Formation Modulates Function at the Quaternary Structural Level* , 2005, Journal of Biological Chemistry.

[42]  D. Gouma,et al.  LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. , 1993, Journal of immunology.

[43]  I. Asplin,et al.  Differential regulation of the fibroblast growth factor (FGF) family by alpha(2)-macroglobulin: evidence for selective modulation of FGF-2-induced angiogenesis. , 2001, Blood.

[44]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[45]  L. Trusolino,et al.  Interactions between growth factor receptors and adhesion molecules: breaking the rules. , 2003, Current opinion in cell biology.

[46]  B. Eliceiri This Review is part of a thematic series on Integrins, which includes the following articles: Integrins and the Myocardium Functional Consequences of Integrin Gene Mutations in Mice Integrins in Vascular Development Integrin and Growth Factor Receptor Crosstalk , 2001 .

[47]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[48]  M. Rusnati,et al.  Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: Role of the low affinity heparin‐like bFGF receptors , 1993, Journal of cellular physiology.

[49]  T. Handel,et al.  Chemokines bind to sulfatides as revealed by surface plasmon resonance. , 2005, Biochimica et biophysica acta.

[50]  J. Turnbull,et al.  Heparan sulfate: decoding a dynamic multifunctional cell regulator. , 2001, Trends in cell biology.

[51]  M. Redondo-Horcajo,et al.  Solution Structure and Interaction with Basic and Acidic Fibroblast Growth Factor of a 3-kDa Human Platelet Factor-4 Fragment with Antiangiogenic Activity* 210 , 2001, The Journal of Biological Chemistry.

[52]  G. Woude,et al.  HGF/SF-Met signaling in tumor progression , 2005, Cell Research.

[53]  B. Matthews,et al.  Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Lyon,et al.  Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. , 2003, Biochemical Society transactions.

[55]  F. Amalric,et al.  Fibroblast Growth Factor-2 Binds to the Regulatory β Subunit of CK2 and Directly Stimulates CK2 Activity toward Nucleolin* , 1996, The Journal of Biological Chemistry.

[56]  I. Asplin,et al.  The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. , 2000, The Journal of biological chemistry.

[57]  Marco Presta,et al.  Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. , 2005, Current pharmaceutical design.

[58]  E. Di Cera,et al.  Thrombin Functions through Its RGD Sequence in a Non-canonical Conformation* , 2005, Journal of Biological Chemistry.

[59]  K. Kimata,et al.  Hepatocyte growth factor immobilized onto culture substrates through heparin and matrigel enhances DNA synthesis in primary rat hepatocytes. , 1994, Experimental cell research.

[60]  T. Muramatsu,et al.  Human Ryudocan from Endothelium-like Cells Binds Basic Fibroblast Growth Factor, Midkine, and Tissue Factor Pathway Inhibitor (*) , 1996, The Journal of Biological Chemistry.

[61]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[62]  L. Kemény,et al.  Identification of a soluble interleukin-8 inhibitor in the supernatant of polymorphonuclear leukocytes. , 1998, Immunology letters.

[63]  G. Neufeld,et al.  The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. , 2002, Advances in experimental medicine and biology.

[64]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[65]  M. Capogrossi,et al.  Platelet-derived Growth Factor-BB and Basic Fibroblast Growth Factor Directly Interact in Vitro with High Affinity* , 2002, The Journal of Biological Chemistry.

[66]  J. Heino,et al.  Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. , 1992, The Journal of biological chemistry.

[67]  Dan M. Bolser,et al.  Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map) , 2005, Bioinform..

[68]  D. Spillmann,et al.  More to "heparin" than anticoagulation. , 1994, Thrombosis research.

[69]  M. Giacca,et al.  Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. , 2005, Blood.

[70]  K. Norrby 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165‐mediated mammalian angiogenesis , 2000, International journal of experimental pathology.

[71]  K. Kent,et al.  Activation of integrin receptors is required for growth factor-induced smooth muscle cell dysfunction. , 2000, Journal of vascular surgery.

[72]  D. Ribatti The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review , 2005, British journal of haematology.

[73]  A. Sahni,et al.  Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3 , 2004 .

[74]  J. Massagué,et al.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system , 1991, Cell.

[75]  P. Monini,et al.  IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. , 1999, Journal of immunology.

[76]  I. Bernard-Pierrot,et al.  Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.

[77]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[78]  U. Cavallaro,et al.  Fibronectin modulates endothelial response to HIV type 1 Tat. , 1997, AIDS research and human retroviruses.

[79]  T. Nakamura,et al.  Hepatocyte Growth Factor/Scatter Factor Binds with High Affinity to Dermatan Sulfate* , 1998, The Journal of Biological Chemistry.

[80]  G. Camenisch,et al.  ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * , 2002, The Journal of Biological Chemistry.

[81]  R. Gallo,et al.  The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Lyon,et al.  Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. , 1994, The Journal of biological chemistry.

[83]  K. Matsumoto,et al.  Hepatocyte growth factor specifically binds to sulfoglycolipids. , 1994, The Journal of biological chemistry.

[84]  A. Nel,et al.  Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. , 1999, Journal of immunology.

[85]  Marco Presta,et al.  αvβ3-integrin-dependent activation of focal adhesion kinase mediates NF-κB activation and motogenic activity by HIV-1 Tat in endothelial cells , 2005, Journal of Cell Science.

[86]  S. Jimenez,et al.  Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[88]  R. Hebbel,et al.  Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.

[89]  A. Östman PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma , 2004 .

[90]  P. Wingfield,et al.  Heparin Binding and Oligomerization of Hepatocyte Growth Factor/Scatter Factor Isoforms , 1997, The Journal of Biological Chemistry.

[91]  Takashi Morita,et al.  Identification of Vascular Endothelial Growth Factor Receptor-binding Protein in the Venom of Eastern Cottonmouth , 2005, Journal of Biological Chemistry.

[92]  T. McCaffrey,et al.  Protection of transforming growth factor β activity by heparin and fucoidan , 1994 .

[93]  M. Nasu,et al.  Bioactivity of the Vascular Endothelial Growth Factor Trapped in Fibrin Clots: Production of IL-6 and IL-8 in Monocytes by Fibrin Clots , 2001, Pathophysiology of Haemostasis and Thrombosis.

[94]  T. Muramatsu,et al.  Midkine binds specifically to sulfatide the role of sulfatide in cell attachment to midkine-coated surfaces. , 2000, European journal of biochemistry.

[95]  D. Rifkin,et al.  Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1 , 1998 .

[96]  M. Plank,et al.  The Role of the Angiopoietins in Tumour Angiogenesis , 2004, Growth factors.

[97]  D. Sane,et al.  Vascular Origin of a Soluble Truncated Form of the Hepatocyte Growth Factor Receptor (c-met) , 2002, Circulation research.

[98]  Y. Gho,et al.  Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.

[99]  Raghu Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Ron Shamir,et al.  PIVOT: Protein Interacions VisualizatiOn Tool , 2004, Bioinform..

[101]  R. Schwall,et al.  Sulfated Oligosaccharides Promote Hepatocyte Growth Factor Association and Govern Its Mitogenic Activity (*) , 1995, The Journal of Biological Chemistry.

[102]  K. Garcia,et al.  The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. , 2000, The Journal of biological chemistry.

[103]  T. Sasaki,et al.  Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. , 1998, European journal of biochemistry.

[104]  A. Sahni,et al.  Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. , 2000, Blood.

[105]  D. Ribatti,et al.  Undersulfated and glycol-split heparins endowed with antiangiogenic activity. , 2004, Journal of medicinal chemistry.

[106]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[107]  I. Screpanti,et al.  Human immunodeficiency virus type 1 tat protein modulates fibronectin expression in thymic epithelial cells and impairs in vitro thymocyte development. , 1996, Cellular immunology.

[108]  X. Wu,et al.  A Two-site Model for ApoB Degradation in HepG2 Cells* , 1997, The Journal of Biological Chemistry.

[109]  K. Zou,et al.  LDL receptor-related protein as a component of the midkine receptor. , 2000, Biochemical and biophysical research communications.

[110]  A. Albini,et al.  Thrombospondin‐1 inhibits Kaposi's sarcoma (KS) cell and HIV‐1 Tat‐induced angiogenesis and is poorly expressed in KS lesions , 1999, The Journal of pathology.

[111]  J. Weatherbee,et al.  Transforming growth factor‐β1 binds to immobilized fibronectin , 1989 .

[112]  R. Tanzi,et al.  Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands , 2000, Nature Medicine.

[113]  Asif Ahmed,et al.  Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.

[114]  S. Soker,et al.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[115]  M. Nugent,et al.  pH Regulates Vascular Endothelial Growth Factor Binding to Fibronectin , 2004, Journal of Biological Chemistry.

[116]  E. Ruoslahti,et al.  A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin , 1993, The Journal of cell biology.

[117]  M. Giacca,et al.  Internalization of HIV-1 Tat Requires Cell Surface Heparan Sulfate Proteoglycans* , 2001, The Journal of Biological Chemistry.

[118]  Y. Gho,et al.  Specific interaction of VEGF165 with β‐amyloid, and its protective effect on β‐amyloid‐induced neurotoxicity , 2005 .

[119]  K. Hayashi,et al.  Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan , 1992, The Journal of cell biology.

[120]  D. Rifkin,et al.  Plasminogen activators and matrix metalloproteinases in angiogenesis. , 1996, Enzyme & protein.

[121]  H Lortat-Jacob,et al.  Pentosan Polysulfate as an Inhibitor of Extracellular HIV-1 Tat* , 2001, The Journal of Biological Chemistry.

[122]  F. Carraro,et al.  Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.

[123]  J. Riordan,et al.  Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[124]  A. Pozzi,et al.  Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. , 1992, EXS.

[125]  Erkki Ruoslahti,et al.  Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels , 2003, The Journal of cell biology.

[126]  N. Kaminski,et al.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.

[127]  S. Stringer,et al.  Interaction of platelet factor 4 with fibroblast growth factor 2 is stabilised by heparan sulphate. , 2003, The international journal of biochemistry & cell biology.

[128]  A. Baird,et al.  Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. , 1995, Investigative ophthalmology & visual science.

[129]  S. Ladisch,et al.  Ganglioside GD1a enhances VEGF-induced endothelial cell proliferation and migration. , 2001, Biochemical and biophysical research communications.

[130]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[131]  Marco Presta,et al.  αvβ3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells , 1997 .

[132]  G. Barillari,et al.  The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. , 1999, Blood.

[133]  Z. Fuks,et al.  Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis , 1990, Cancer and Metastasis Reviews.

[134]  D. Rifkin,et al.  Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. , 1989, The Journal of biological chemistry.

[135]  S. L. Gonias,et al.  Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[136]  A. Sahni,et al.  Fibrinogen binding potentiates FGF‐2 but not VEGF induced expression of u‐PA, u‐PAR, and PAI‐1 in endothelial cells , 2004, Journal of thrombosis and haemostasis : JTH.

[137]  A. Prats,et al.  Antiangiogenic Properties of Fibstatin, an Extracellular FGF-2–Binding Polypeptide , 2004, Cancer Research.

[138]  A. Bikfalvi,et al.  Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. , 1999, Blood.

[139]  Andreas Sommer,et al.  Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): Identification of two Asp‐Gly‐Arg‐Containing domains involved in the mitogenic activity of bFGF in endothelial cells , 1991, Journal of cellular physiology.

[140]  L. Pellegrini,et al.  Role of heparan sulfate in fibroblast growth factor signalling: a structural view. , 2001, Current opinion in structural biology.

[141]  A. Bikfalvi Platelet factor 4: an inhibitor of angiogenesis. , 2004, Seminars in thrombosis and hemostasis.

[142]  L. Lowe-Krentz,et al.  Heparin releasable and nonreleasable forms of heparan sulfate proteoglycan are found on the surfaces of cultured porcine aortic endothelial cells , 1992, Molecular and Cellular Biochemistry.

[143]  Y. Takada,et al.  Specific Interaction of Angiostatin with Integrin αvβ3 in Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[144]  Richard G. W. Anderson,et al.  Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Controls Endocytosis and c-CBL-mediated Ubiquitination of the Platelet-derived Growth Factor Receptor β (PDGFRβ)* , 2005, Journal of Biological Chemistry.

[145]  T. Ferkol,et al.  IL-8 Released Constitutively by Primary Bronchial Epithelial Cells in Culture Forms an Inactive Complex with Secretory Component1 , 2001, The Journal of Immunology.

[146]  M. Rusnati,et al.  Heparin derivatives as angiogenesis inhibitors. , 2003, Current pharmaceutical design.

[147]  F. Soncin,et al.  Interaction of Heparin with Human Angiogenin* , 1997, The Journal of Biological Chemistry.

[148]  M. Nugent,et al.  Regulation of Vascular Endothelial Growth Factor Binding and Activity by Extracellular pH* , 2003, Journal of Biological Chemistry.

[149]  D. Webb,et al.  Transforming growth factor beta isoform 2-specific high affinity binding to native alpha 2-macroglobulin. Chimeras identify a sequence that determines affinity for native but not activated alpha 2-macroglobulin. , 1994, The Journal of biological chemistry.

[150]  G. Neufeld,et al.  Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis , 2004, Cancer Research.

[151]  H. Ueno,et al.  A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. , 1992, The Journal of biological chemistry.

[152]  T L Blundell,et al.  Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor , 2001, The EMBO journal.

[153]  D. Spillmann,et al.  Defining the Interleukin-8-binding Domain of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[154]  P. Dell’Era,et al.  Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts , 2002, Oncogene.

[155]  G. Taraboletti,et al.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. , 2003, Cancer research.

[156]  M. Rusnati,et al.  Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. , 1994, The Biochemical journal.

[157]  P. Bornstein,et al.  Thrombospondin 2, a matricellular protein with diverse functions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[158]  G. Martiny-Baron,et al.  Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. , 1997, Cancer research.

[159]  L. Szilák,et al.  Interleukin-8 binds to syndecan-2 on human endothelial cells. , 2004, The Biochemical journal.

[160]  G. Davis,et al.  This Review Is Part of a Thematic Series on Vascular Cell Diversity, Which Includes the following Articles: Heart Valve Development: Endothelial Cell Signaling and Differentiation Molecular Determinants of Vascular Smooth Muscle Cell Diversity Endothelial/pericyte Interactions Endothelial Extracellu , 2022 .

[161]  K. Preissner,et al.  Molecular Interactions and Functional Interference between Vitronectin and Transforming Growth Factor-β , 2002, Laboratory Investigation.

[162]  H. Vetter,et al.  Gangliosides GM1, GM2 and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms. , 1996, European journal of cell biology.

[163]  E. Chambaz,et al.  Alpha 2-macroglobulin: a binding protein for transforming growth factor-beta and various cytokines. , 1996, Hormone research.

[164]  M. Rusnati,et al.  Functional Domains of Basic Fibroblast Growth Factor: Possible Role of Asp‐Gly‐Arg Sequences in the Mitogenic Activity of bFGF , 1991, Annals of the New York Academy of Sciences.

[165]  P. Maher,et al.  High affinity immunoreactive FGF receptors in the extracellular matrix of vascular endothelial cells--implications for the modulation of FGF-2 , 1995, The Journal of cell biology.

[166]  T. Nakamura,et al.  Collagens in the liver extracellular matrix bind hepatocyte growth factor. , 1998, Gastroenterology.

[167]  S. Soker,et al.  In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.

[168]  M. Rusnati,et al.  Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form , 1989, Journal of cellular physiology.

[169]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[170]  M. Giacca,et al.  The Basic Domain in HIV-1 Tat Protein as a Target for Polysulfonated Heparin-mimicking Extracellular Tat Antagonists* , 1998, The Journal of Biological Chemistry.

[171]  M. Maio,et al.  Differential levels of soluble endoglin (CD105) in myeloid malignancies , 2003, Journal of cellular physiology.

[172]  Álvaro R. Osornio-Vargas,et al.  Differential Binding and Regulation of Platelet-derived Growth Factor A and B Chain Isoforms by α2-Macroglobulin (*) , 1995, The Journal of Biological Chemistry.

[173]  M. Rusnati,et al.  Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans , 1996, International journal of clinical & laboratory research.

[174]  Antonio Facchiano,et al.  Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor. , 2002, Blood.

[175]  M. Tessier-Lavigne,et al.  Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function , 2003, Nature.

[176]  M. Giacca,et al.  Interaction of HIV-1 Tat Protein with Heparin , 1997, The Journal of Biological Chemistry.

[177]  P. Hogg,et al.  Interaction of platelet-derived growth factor with thrombospondin 1. , 1997, The Biochemical journal.

[178]  D. Ribatti,et al.  Integrin &agr;V&bgr;3 as a Target for Blocking HIV-1 Tat-Induced Endothelial Cell Activation In Vitro and Angiogenesis In Vivo , 2005 .

[179]  M. Lyon,et al.  The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.

[180]  M. Giacca,et al.  Identification of Specific Molecular Structures of Human Immunodeficiency Virus Type 1 Tat Relevant for Its Biological Effects on Vascular Endothelial Cells , 2000, Journal of Virology.

[181]  A. Isacchi,et al.  Characterization of a biologically active extracellular domain of fibroblast growth factor receptor 1 expressed in Escherichia coli. , 1992, European journal of biochemistry.

[182]  R. Ross,et al.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[183]  T. Shiomi,et al.  Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF‐induced angiogenesis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[184]  C. McArthur,et al.  Amplification of extracellular matrix and oncogenes in tat-transfected human salivary gland cell lines with expression of laminin, fibronectin, collagens I, III, IV, c-myc and p53. , 2001, Archives of oral biology.

[185]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[186]  D. Rifkin,et al.  Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor , 1990, The Journal of cell biology.

[187]  R. Ross,et al.  Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences , 1992, The Journal of cell biology.

[188]  M. Mrksich,et al.  Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.

[189]  M. Noda,et al.  α4β1- and α6β1-integrins are functional receptors for midkine, a heparin-binding growth factor , 2004, Journal of Cell Science.

[190]  N. Galili,et al.  Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. , 2000, Cancer research.

[191]  Y. Tabata,et al.  Type I collagen can function as a reservoir of basic fibroblast growth factor. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[192]  David C West,et al.  Interactions of Multiple Heparin Binding Growth Factors with Neuropilin-1 and Potentiation of the Activity of Fibroblast Growth Factor-2* , 2005, Journal of Biological Chemistry.

[193]  D. Schuppan,et al.  Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans. , 2005, Biochemical and biophysical research communications.

[194]  G. Plowman,et al.  Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[195]  A. Sahni,et al.  FGF‐2 but not FGF‐1 binds fibrin and supports prolonged endothelial cell growth , 2003, Journal of thrombosis and haemostasis : JTH.

[196]  D. Gospodarowicz,et al.  Heparin protects basic and acidic FGF from inactivation , 1986, Journal of cellular physiology.

[197]  J. Courty,et al.  Pleiotrophin inhibits HIV infection by binding the cell surface‐expressed nucleolin , 2005, The FEBS journal.

[198]  M. Ziche,et al.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. , 1999, Molecular biology of the cell.

[199]  R. Alon,et al.  TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. , 1994, Journal of immunology.

[200]  A. Aszódi,et al.  Functional consequences of integrin gene mutations in mice. , 2001, Circulation research.

[201]  E. Nilsson,et al.  On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. , 1991, The Journal of clinical investigation.

[202]  James R. Knight,et al.  A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae , 2000, Nature.

[203]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[204]  K. J. Brown,et al.  Histidine-rich glycoprotein and platelet factor 4 mask heparan sulfate proteoglycans recognized by acidic and basic fibroblast growth factor. , 1994, Biochemistry.

[205]  Marco Presta,et al.  Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[206]  Q. Yu,et al.  Angiopoietin-3 Is Tethered on the Cell Surface via Heparan Sulfate Proteoglycans* , 2004, Journal of Biological Chemistry.

[207]  M. Iruela-Arispe,et al.  Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.

[208]  P. Dijke,et al.  TGF-h receptor function in the endothelium , 2005 .

[209]  F. López‐Casillas,et al.  Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. , 2001 .

[210]  Dan M. Bolser,et al.  Visualisation and graph-theoretic analysis of a large-scale protein structural interactome , 2003, BMC Bioinformatics.

[211]  R. Iozzo,et al.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. , 2001, The Journal of clinical investigation.

[212]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[213]  Shay Soker,et al.  VEGF165 mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF165‐receptor binding , 2002, Journal of cellular biochemistry.

[214]  D. Ribatti,et al.  Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. , 2001, The Journal of biological chemistry.

[215]  A. Bikfalvi,et al.  Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. , 1998, Blood.

[216]  M. Giacca,et al.  Thrombospondin‐1/HIV‐1 Tat protein interaction: modulation of the biological activity of extracellular Tat , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[217]  H. Avraham,et al.  VEGF165 requires extracellular matrix components to induce mitogenic effects and migratory response in breast cancer cells , 2001, Oncogene.

[218]  E. Ruoslahti,et al.  Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β3Integrin through Its Extracellular Domain* , 2000, The Journal of Biological Chemistry.

[219]  A. Mori,et al.  TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. , 2000, International journal of oncology.

[220]  Wen-Fang Tseng,et al.  LRP‐1/TβR‐V mediates TGF‐β1‐induced growth inhibition in CHO cells , 2004 .

[221]  M. O’Connor-McCourt,et al.  Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. , 1987, The Journal of biological chemistry.

[222]  E. Papadimitriou,et al.  Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. , 2004, The international journal of biochemistry & cell biology.

[223]  S. Ladisch,et al.  Shedding of gangliosides by human medulloblastoma cells. , 1997, Experimental cell research.

[224]  D. Hicklin,et al.  Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. , 1994, The Journal of biological chemistry.

[225]  G. Taraboletti,et al.  The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[226]  Benito Casu,et al.  Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. , 2004, Glycobiology.

[227]  G. Neufeld,et al.  Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[228]  I. Vlodavsky,et al.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. , 2001, The Journal of clinical investigation.

[229]  Barbara Bottazzi,et al.  PTX3 inhibits angiogenesis Selective recognition of fibroblast growth factor-2 by the long pentraxin , 2013 .

[230]  John M. Whitelock,et al.  The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.